Health Care [ 5/12 ] | Biotechnology [ 25/74 ]
NASDAQ | Common Stock
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.
Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions.
The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001.
Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 7, 25 | -0.64 Increased by +28.72% | - |
| Nov 4, 24 | -1.91 Decreased by -60.78% | -0.40 Decreased by -376.63% |
| Aug 27, 24 | -2.22 Decreased by -79.73% | - |
| Apr 26, 24 | -1.66 Decreased by -48.32% | - |
| Feb 2, 24 | -0.90 Increased by +7.82% | - |
| Nov 7, 23 | -1.19 Increased by +38.96% | - |
| Jul 24, 23 | -1.23 Increased by +52.97% | - |
| May 9, 23 | -1.12 Increased by +58.86% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|